^
    15h
    SKB264-ANLO: Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, China Medical University, China
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    18h
    LIBRA: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=278, Recruiting, AstraZeneca | Trial primary completion date: Mar 2027 --> Apr 2029
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    19h
    Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer. (PubMed, Br J Cancer)
    The study highlights SG's clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy)
    2d
    A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jul 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk)
    3d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    4d
    EVER-132-001: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    4d
    Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort. (PubMed, Clin Transl Oncol)
    In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    5d
    TROPICS-03: Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Trodelvy (sacituzumab govitecan-hziy)
    6d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    6d
    A Clinical Study on the Use of Yuyang Mouthwash for the Prevention of Grade ≥2 Sacituzumab Govitecan–Associated Oral Mucositis (ChiCTR2500114861)
    P=N/A, N=303, Not yet recruiting, Beijing Luhe Medical College Affiliated to Capital Medical University; Beijing Luhe Medical College Affiliated to Capital Medical University
    New trial
    |
    Trodelvy (sacituzumab govitecan-hziy)
    6d
    Switching to Sacituzumab Govitecan Combined Toripalimab in TNBC Patients:Tumor Non-Response After the First Stage of NC A Single-Arm Clinical Study to Explore the Efficacy and Safety (ChiCTR2500112392)
    P=N/A, N=31, Not yet recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    6d
    The Pilot Study on Sacituzumab tirumotecan (SKB264) for the Treatment of Recurrent Adamantinomatous Craniopharyngioma (ACP) (ChiCTR2500111542)
    P=N/A, N=12, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University
    New trial
    |
    Jiataile (sacituzumab tirumotecan)